

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Indicator Equality Impact Assessment

### **IND182 Diabetes: statins for primary prevention of CVD (T2DM and 10% risk)**

1.1 Have any potential equality issues been identified during the development process?

No equality issues have been identified.

1.2 Have any population groups, treatments or settings been excluded from coverage by the indicator? Are these exclusions justified – that is, are the reasons legitimate and the exclusion proportionate?

This indicator focusses on people with type 2 diabetes without moderate or severe frailty. People with type 1 diabetes are the focus of indicator IND166.

Focusing on people without moderate or severe frailty aims to reduce under-treatment and support better control of biomedical targets through individualised, patient-centred care.

1.3 Does the indicator make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The indicator does not affect access for different groups.

1.4 Is there potential for the indicator to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No potential impact has been identified.

Completed by lead technical analyst: Stacy Wilkinson

Date 27.09.18

Approved by NICE quality assurance lead: Craig Grime

Date 04.10.18

© NICE 2018. All rights reserved. Subject to [Notice of rights](#).